西妥昔-话题@MedSci

#西妥昔#

72篇内容 | 2293人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1679478, encodeId=21fa16e94780c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, objectType=article, longId=727754, objectId=ef63e277540f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef63e277540f, replyNumber=0, likeNumber=126, createdTime=2022-12-14, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef63e277540f, moduleTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef63e277540f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679476, encodeId=b69f16e947674, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, objectType=article, longId=300705, objectId=242e300e0568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242e300e0568, replyNumber=0, likeNumber=96, createdTime=2022-10-29, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242e300e0568, moduleTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242e300e0568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679477, encodeId=0e3a16e94778c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Clin Cancer Res：西妥昔单抗+纳武单抗联合治疗复发/转移性头颈部鳞癌, objectType=article, longId=723523, objectId=d89be23523ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89be23523ff, replyNumber=0, likeNumber=86, createdTime=2022-06-26, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89be23523ff, moduleTitle=Clin Cancer Res：西妥昔单抗+纳武单抗联合治疗复发/转移性头颈部鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89be23523ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679472, encodeId=32b016e9472a0, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, objectType=article, longId=219629, objectId=09d321962921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09d321962921, replyNumber=0, likeNumber=81, createdTime=2022-02-02, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09d321962921, moduleTitle=Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09d321962921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679474, encodeId=387416e9474ec, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=西妥昔单抗联合FOLFIRI 双周方案在野生型K．Ras 基因晚期结直肠癌患者中的Ⅱ期临床观察, objectType=article, longId=220892, objectId=769f22089252, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769f22089252, replyNumber=0, likeNumber=82, createdTime=2022-04-17, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769f22089252, moduleTitle=西妥昔单抗联合FOLFIRI 双周方案在野生型K．Ras 基因晚期结直肠癌患者中的Ⅱ期临床观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=769f22089252)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679469, encodeId=f4db16e9469ee, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, objectType=article, longId=211288, objectId=122f21128838, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=122f21128838, replyNumber=0, likeNumber=99, createdTime=2021-10-02, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=122f21128838, moduleTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=122f21128838)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Eur J Cancer：铂类+5-氟尿嘧啶+西妥昔单抗可作为中国复发/转移性头颈鳞癌患者的新一线治疗方案！, objectType=article, longId=216219, objectId=7cde216219cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cde216219cc, replyNumber=0, likeNumber=83, createdTime=2021-08-27, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cde216219cc, moduleTitle=Eur J Cancer：铂类+5-氟尿嘧啶+西妥昔单抗可作为中国复发/转移性头颈鳞癌患者的新一线治疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cde216219cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679475, encodeId=3ff516e947500, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, objectType=article, longId=221205, objectId=3c79221205ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c79221205ea, replyNumber=0, likeNumber=85, createdTime=2021-12-05, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c79221205ea, moduleTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c79221205ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679473, encodeId=fd2316e947346, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Cancers：皮肤毒性(ST) 预测RAS野生型转移性结直肠癌西妥昔单抗联合avelumab再挑战治疗的疗效, objectType=article, longId=220587, objectId=fda922058e46, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fda922058e46, replyNumber=0, likeNumber=67, createdTime=2021-12-21, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fda922058e46, moduleTitle=Cancers：皮肤毒性(ST) 预测RAS野生型转移性结直肠癌西妥昔单抗联合avelumab再挑战治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fda922058e46)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679471, encodeId=186816e9471d6, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性, objectType=article, longId=217042, objectId=d10c21e042bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d10c21e042bc, replyNumber=0, likeNumber=71, createdTime=2022-03-23, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d10c21e042bc, moduleTitle=ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d10c21e042bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679467, encodeId=b6b716e9467cd, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, objectType=article, longId=203464, objectId=b4f620346485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f620346485, replyNumber=0, likeNumber=84, createdTime=2021-03-17, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f620346485, moduleTitle=Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f620346485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679465, encodeId=7dc516e94657d, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后, objectType=article, longId=201449, objectId=7c8f201449ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c8f201449ff, replyNumber=0, likeNumber=77, createdTime=2021-05-16, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c8f201449ff, moduleTitle=Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c8f201449ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679468, encodeId=291516e946878, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=J Clin Oncol：Encorafenib+西妥昔单抗，BRAF V600E突变型转移性结直肠癌患者的新选择！, objectType=article, longId=206364, objectId=b9a1206364ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9a1206364ab, replyNumber=0, likeNumber=88, createdTime=2021-04-03, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9a1206364ab, moduleTitle=J Clin Oncol：Encorafenib+西妥昔单抗，BRAF V600E突变型转移性结直肠癌患者的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a1206364ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679461, encodeId=7afb16e946196, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet Gastroen Hepatol:131I-西妥昔单抗辅助治疗改善肝癌切除患者预后, objectType=article, longId=189718, objectId=d0d9189e18a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0d9189e18a2, replyNumber=0, likeNumber=115, createdTime=2020-08-01, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0d9189e18a2, moduleTitle=Lancet Gastroen Hepatol:131I-西妥昔单抗辅助治疗改善肝癌切除患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0d9189e18a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679466, encodeId=181416e94660c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JCO：西妥昔单抗联合放疗治疗晚期头颈部鳞状细胞癌疗效次于顺铂, objectType=article, longId=202297, objectId=bcfe20229e68, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcfe20229e68, replyNumber=0, likeNumber=82, createdTime=2021-02-28, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcfe20229e68, moduleTitle=JCO：西妥昔单抗联合放疗治疗晚期头颈部鳞状细胞癌疗效次于顺铂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcfe20229e68)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679464, encodeId=38d416e94642f, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者, objectType=article, longId=198494, objectId=6962198494d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6962198494d6, replyNumber=0, likeNumber=92, createdTime=2020-10-13, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6962198494d6, moduleTitle=Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6962198494d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679463, encodeId=cad016e9463f0, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性, objectType=article, longId=196267, objectId=c95e19626e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95e19626e25, replyNumber=0, likeNumber=168, createdTime=2020-08-14, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95e19626e25, moduleTitle=Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c95e19626e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679462, encodeId=0e8516e946231, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, objectType=article, longId=191946, objectId=1e43191946c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e43191946c0, replyNumber=0, likeNumber=80, createdTime=2020-10-08, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e43191946c0, moduleTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e43191946c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679460, encodeId=854016e9460cb, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet Oncol：系统化疗联合西妥昔单抗不能用于早期可切除结肠癌肝转移患者, objectType=article, longId=187238, objectId=b28718e23873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b28718e23873, replyNumber=0, likeNumber=91, createdTime=2020-06-09, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b28718e23873, moduleTitle=Lancet Oncol：系统化疗联合西妥昔单抗不能用于早期可切除结肠癌肝转移患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b28718e23873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679457, encodeId=0d7216e9457db, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=捷报频传！张力教授团队再次报道肺癌EGFR 20ins治疗新方案：奥希替尼+西妥昔单抗成为潜力之选！, objectType=article, longId=179495, objectId=b44d1e9495ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b44d1e9495ef, replyNumber=0, likeNumber=93, createdTime=2020-08-23, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b44d1e9495ef, moduleTitle=捷报频传！张力教授团队再次报道肺癌EGFR 20ins治疗新方案：奥希替尼+西妥昔单抗成为潜力之选！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b44d1e9495ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

西妥昔

2020-05-29

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效

2022-12-14

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS

2022-10-29

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Clin Cancer Res：西妥昔单抗+纳武单抗联合治疗复发/转移性头颈部鳞癌

2022-06-26

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Front Oncol：每周PCC方案（紫杉醇+卡铂+西妥昔单抗）可用于不适合EXTREME方案治疗复发和/或转移性头颈部鳞状细胞癌（R/M-HNSCC）患者

2022-02-02

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

西妥昔单抗联合FOLFIRI 双周方案在野生型K．Ras 基因晚期结直肠癌患者中的Ⅱ期临床观察

2022-04-17

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性

2021-10-02

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Eur J Cancer：铂类+5-氟尿嘧啶+西妥昔单抗可作为中国复发/转移性头颈鳞癌患者的新一线治疗方案！

2021-08-27

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究

2021-12-05

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Cancers：皮肤毒性(ST) 预测RAS野生型转移性结直肠癌西妥昔单抗联合avelumab再挑战治疗的疗效

2021-12-21

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性

2022-03-23

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Br J Cancer：FOLFIRI治疗方案与西妥昔单抗或贝伐单抗联合治疗晚期结直肠癌的FIRE-3 3期随机临床研究

2021-03-17

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Br J Cancer：Buparlisib和西妥昔单抗联合治疗改善头颈部鳞状细胞癌患者预后

2021-05-16

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

J Clin Oncol：Encorafenib+西妥昔单抗，BRAF V600E突变型转移性结直肠癌患者的新选择！

2021-04-03

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet Gastroen Hepatol:131I-西妥昔单抗辅助治疗改善肝癌切除患者预后

2020-08-01

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JCO：西妥昔单抗联合放疗治疗晚期头颈部鳞状细胞癌疗效次于顺铂

2021-02-28

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者

2020-10-13

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性

2020-08-14

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌

2020-10-08

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet Oncol：系统化疗联合西妥昔单抗不能用于早期可切除结肠癌肝转移患者

2020-06-09

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

捷报频传！张力教授团队再次报道肺癌EGFR 20ins治疗新方案：奥希替尼+西妥昔单抗成为潜力之选！

2020-08-23

科室
- - 订阅+
  - 更多科室
工具
服务